These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial. Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000 [TBL] [Abstract][Full Text] [Related]
30. Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome. Liu S; Li C; Tang MW; Xu WS; Chen KQ; Sui X; Tian XL; Xu KF Chin Med J (Engl); 2019 Oct; 132(19):2378-2379. PubMed ID: 31503058 [No Abstract] [Full Text] [Related]
31. Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib. Noell C; Arbeit R; Kanhoush R Dermatol Online J; 2018 Jan; 24(1):. PubMed ID: 29469766 [TBL] [Abstract][Full Text] [Related]
32. Lung Disease: A Rare but Devastating Complication of Systemic Juvenile Idiopathic Arthritis and the Use of Tofacitinib as a Treatment. Kaplan MM; Cinel G; Çelikel E Arch Bronconeumol; 2024 Jun; 60(6):374-375. PubMed ID: 38402050 [No Abstract] [Full Text] [Related]
34. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea. Lee MY; Park SK; Park SY; Byun JH; Lee SM; Ko SK; Lee EK Clin Ther; 2015 Aug; 37(8):1662-76.e2. PubMed ID: 26243076 [TBL] [Abstract][Full Text] [Related]
35. Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme. Curtis JR; Lee EB; Martin G; Mariette X; Terry KK; Chen Y; Geier J; Andrews J; Kaur M; Fan H; Nduaka CI Clin Exp Rheumatol; 2017; 35(4):614-622. PubMed ID: 28240592 [TBL] [Abstract][Full Text] [Related]
36. Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever. Gök K; Cengiz G; Erol K; Ozgocmen S Acta Reumatol Port; 2017; 42(1):88-90. PubMed ID: 28371574 [TBL] [Abstract][Full Text] [Related]
37. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. Craiglow BG; King BA JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994 [TBL] [Abstract][Full Text] [Related]
38. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Winthrop KL; Silverfield J; Racewicz A; Neal J; Lee EB; Hrycaj P; Gomez-Reino J; Soma K; Mebus C; Wilkinson B; Hodge J; Fan H; Wang T; Bingham CO Ann Rheum Dis; 2016 Apr; 75(4):687-95. PubMed ID: 25795907 [TBL] [Abstract][Full Text] [Related]
39. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis]. Sonomoto K; Tanaka Y Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331 [TBL] [Abstract][Full Text] [Related]
40. Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation. Pérez-Román DI; Ortiz-Haro AB; Ruiz-Medrano E; Contreras-Yáñez I; Pascual-Ramos V Rheumatol Int; 2018 Apr; 38(4):599-606. PubMed ID: 29264637 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]